Management of acute decompensated heart failure

Allen, Larry A.; O'Connor, Christopher M.
March 2007
CMAJ: Canadian Medical Association Journal;3/13/2007, Vol. 176 Issue 6, p797
Academic Journal
Acute decompensated heart failure represents a heterogeneous group of disorders that typically present as dyspnea, edema and fatigue. Despite the high prevalence of this condition and its associated major morbidity and mortality, diagnosis can be difficult, and optimal treatment remains poorly defined. Identification of the acute triggers for the decompensation as well as noninvasive characterization of cardiac filling pressures and output is central to management. Diuretics, vasodilators, continuous positive airway pressure and inotropes can be used to alleviate symptoms. However, few agents currently available for the treatment of acute decompensated heart failure have been definitively shown in large prospective randomized clinical trials to provide meaningful improvements in intermediate-term clinical outcomes. Multiple novel therapies are being developed, but previous treatment failures indicate that progress in the management of acute decompensated heart failure is likely to be slow.


Related Articles

  • Should treatment for heart failure with preserved ejection fraction differ from that for heart failure with reduced ejection fraction? Jong, Philip; McKelvie, Robert; Yusuf, Salim // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;8/28/2010, Vol. 341 Issue 7770, p453 

    In this article, the authors seek to clarify whether treatments that are effective in heart failure with reduced ejection fraction (HF-REF) may also be effective in heart failure with preserved ejection fraction (HP-PEF). Data on studies that tested treatments for HF-REF and HP-PEF were sorted...

  • Chronic heart failure: pathophysiology, diagnosis and treatment. Nicholson, Christopher // Nursing Older People;Sep2014, Vol. 26 Issue 7, p29 

    Heart failure has significant prevalence in older people: the mean average age of patients with the condition is 77. It has serious prognostic and quality of life implications for patients, as well as health service costs. Diagnosis requires confirmatory investigations and consideration of...

  • 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). Hicks, Karen A; Tcheng, James E; Bozkurt, Biykem; Chaitman, Bernard R; Cutlip, Donald E; Farb, Andrew; Fonarow, Gregg C; Jacobs, Jeffrey P; Jaff, Michael R; Lichtman, Judith H; Limacher, Marian C; Mahaffey, Kenneth W; Mehran, Roxana; Nissen, Steven E; Smith, Eric E; Targum, Shari L; ACC/AHA TASK FORCE ON CLINICAL DATA STANDARDS MEMBERS // Journal of Nuclear Cardiology;Oct2015, Vol. 22 Issue 5, p1041 

    No abstract available.

  • Pharmacological Treatment of Acute Heart Failure: Current Treatment and New Targets. Pöss, J; Link, A; Böhm, M // Clinical Pharmacology & Therapeutics;Oct2013, Vol. 94 Issue 4, p499 

    Acute heart failure (AHF) is defined as the rapid onset of, or changes in, the symptoms and signs of heart failure (HF). It is a life-threatening situation in which diagnosis and initiation of therapy are crucial. The treatment aims are to stabilize the patient, improve clinical symptoms, and...

  • A stiff heart.  // Mayo Clinic Health Letter;Sep2015, Vol. 33 Issue 9, p1 

    The article discusses the two types of heart failure, its mechanisms, and how each reacts to treatment. Topics covered include doctors' measurement of the heart's pumping rate or, ejection fraction, the heart failure with reduced ejection fraction (HFrRF) and the heart failure with preserved...

  • Clinical Trials in Congestive Heart Failure: Why Do Studies Report Conflicting Results? Packer, Milton // Annals of Internal Medicine;7/1/88, Vol. 109 Issue 1, p3 

    Editorial. Comments on the contribution of diagnostic heterogeneity in giving discordant results of clinical trials conducted for the treatment of congestive heart failures. Influence of different criterias used for judging the efficacy of drugs on the results; Impact of different publication...

  • Intravenous Vasodilator Therapy in Congestive Heart Failure. Moazemi, Kourosh; Chana, Jatinder S.; Willard, Anna Marie; Kocheril, Abraham G. // Drugs & Aging;2003, Vol. 20 Issue 7, p485 

    The prevalence of congestive heart failure (CHF) is increasing in the US and worldwide, partly because patients are living longer. Treatment of CHF is mostly on an outpatient basis, but inpatient care is required for decompensated CHF, acute CHF or poor response to outpatient treatment. Control...

  • Calcium, Magnesium, and Diuretics.  // British Medical Journal;1/25/1975, Vol. 1 Issue 5951, p170 

    Examines the use of oral diuretic agents for the treatment of patients with hypertension and heart failure. Toxicology of the drugs; Cause of diabetes mellitus de novo; Effects of diuretics on serum potassium concentration.

  • Siemens, Janssen join forces on diagnostic test.  // Medical Device Daily;6/18/2013, Vol. 17 Issue 117, p4 

    The article reports on an agreement between the companies Siemens Healthcare Diagnostics and Janssen Pharmaceutica to jointly develop a diagnostic test.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics